101 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
from time to time with the Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks … potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.
Clinical trials
424B3
ukaj3x6in3dkv5hdre
18 Mar 24
Prospectus supplement
4:06pm
8-K
EX-10.1
3g9 z5wd24x
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
2qcolz
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
2t1fd rf8
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
8aur9gf2
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
424B3
zox1ymfvb0k2
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-14.1
yw4qd2wn 0ve5m0v2
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
8-K
10w8ljt2fa
5 Feb 24
Entry into a Material Definitive Agreement
7:36am